Results 91 to 100 of about 59,458 (179)

Bradyarrhythmias secondary to topical levobunolol hydrochloride solution

, 2014
Lianjun Lin,* Yuchuan Wang,* Yan Chen, Meilin Liu Geriatric Department, Peking University First Hospital, Beijing, People’s Republic of China *These authors contributed equally to this work Abstract: An 88-year-old man was admitted with fatigue,
Wang YC, Lin LJ, Chen Y, Liu ML
core  

Stress-evoked opioid release inhibits pain in major depressive disorder [PDF]

, 2008
To determine whether stress-evoked release of endogenous opioids might account for hypoalgesia in major depressive disorder (MDD), the μ-opioid antagonist naltrexone (50 mg) or placebo was administered double-blind to 24 participants with MDD and to 31 ...
Frew, A.K., Drummond, P.D.
core  

Dissolving Microneedles with Advanced Design–a Tool for Enhancing Skin Permeation of Naltrexone Hydrochloride

Dissolving microneedles (DMN) could be considered as a promising platform for transdermal delivery of naltrexone hydrochloride (NTX), providing a minimally inva-sive alternative to conventional administration routes. In the present study, DMN patches with an advanced design were developed via a two-step micromoulding tech-nique.
Teodora Popova, Ivaylo Ganchev, Christina Voycheva   +2 more
openaire   +1 more source

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops

, 2008
Eiichi UchioDepartment of Ophthalmology, Fukuoka University School of Medicine, Fukuoka, JapanAbstract: Olopatadine hydrochloride exerts a wide range of pharmacological actions such as histamine H1 receptor antagonist action, chemical mediator ...
Eiichi Uchio
core  

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

, 2015
Anna M Buehler Hospital Alemao Oswaldo Cruz, Institute of Health Education and Sciences, Sao Paulo, BrazilI read with great interest the systematic review by Caixàs et al1 on the effect of naltrexone sustained-release/bupropion sustained-release (
Buehler AM
core  

Naltrexone maintenance treatment

, 2009
Naltrexone was first registered in the US in 19841 and today is available in many countries as a treatment for both heroin and alcohol dependence. This chapter reviews the safety, efficacy, and effectiveness of naltrexone as a maintenance treatment for ...
Ritter, Alison, Gibson, Amy (R17420)
core  

Naltrexone and Nalmefene as Modern Psychopharmacotherapy for Alcohol Use Disorder: Modulation of Opioid Receptors and Neurobiological Pathways of Alcohol Action. [PDF]

Biomedicines
Rząca M, Sroka M, Fus K, Ślebioda D, Kozinska R, Chmiela M, Chłopaś-Konowałek A.   +6 more
europepmc   +1 more source

Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended-Release Tablet (NB-ER) for Weight Maintenance in Adult Patients After a 6-Month Intensive Behaviour Modification Program Combined With Meal Replacements. [PDF]

Clin Obes
Chetty VT, Denescu L, Zevin B, Damjanovic S, Balodis IM, Elsharif A, Foster G.   +6 more
europepmc   +1 more source

New and emerging treatments for PBC-related pruritus. [PDF]

Drugs Context
Anderson SL.
europepmc   +1 more source

Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents. [PDF]

Clin Cosmet Investig Dermatol
Avriyanti E, Larasati R, Rengasamy S, Hidayah RMN, Tsaqilah L, Pangastuti M, Maharani RH.   +6 more
europepmc   +1 more source